Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News AIM ImmunoTech Inc AIM

Healthcare Biotechnology
AIM ImmunoTech Inc. is an immuno-pharma company. It is focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular ribonucleic acid (RNA) molecules, and Alferon N Injection (Interferon alfa). Its lead product is an investigational drug called... see more

Recent & Breaking News (NYSEAM:AIM)

Hemispherx to Present at the 4th Annual Immuno-Oncology: BD&L and Investment Forum

GlobeNewswire May 14, 2018

Hemispherx to Present at the 8th Annual LD Micro Invitational

GlobeNewswire May 10, 2018

Hemispherx Provides an Update to Stockholders Highlighting Cancer Focus and $10 Million Booked Since Start of Year Will Support Increased Production of Ampligen for Immuno-Oncology Clinical Trials

GlobeNewswire May 2, 2018

Hemispherx Announces Pricing of $2.57 Million Registered Direct Offering at a Premium to Market

GlobeNewswire April 20, 2018

Hemispherx Successfully Completes Production of More Than 8,500 Vials of Ampligen for Commercial Sales and Expanded Clinical Programs

GlobeNewswire April 17, 2018

Hemispherx Expands Ampligen Early Access Programme to Canada to Treat ME/CFS Patients

GlobeNewswire April 4, 2018

Hemispherx Biopharma Announced Financial Results for the Year Ended December 31, 2017

GlobeNewswire April 2, 2018

Hemispherx Biopharma and UNMC Partner to Take on Pancreatic Cancer

GlobeNewswire March 14, 2018

Hemispherx to Present at the 30th Annual ROTH Conference

GlobeNewswire March 5, 2018

Hemispherx to Present at the Inaugural LD Micro Virtual Conference

GlobeNewswire February 27, 2018

Hemispherx To Supply Ampligen for Pancreatic Cancer Patients in Canada Under Special Access Program

GlobeNewswire February 26, 2018

Hemispherx’s Ampligen Highlighted in Review of Role of TLR3 Agonist Support for “Universal” Flu Immunization Development Programs

GlobeNewswire January 31, 2018

Hemispherx to Present at the BIO CEO & Investor Conference

GlobeNewswire January 29, 2018

Hemispherx Announces Presentation on the Potential Role of Ampligen as an Immune System Amplifier Improving Seasonal Flu Vaccine Cross-Protection

GlobeNewswire January 26, 2018

Hemispherx Announces Data Presentation on the Potential for Ampligen to Improve Cancer Outcomes with Checkpoint Inhibitors

GlobeNewswire January 25, 2018

Hemispherx Comments on $500+ Million Market Opportunity for Ampligen®, the Only Late Stage ME/CFS Candidate in the U.S.

GlobeNewswire January 23, 2018

Hemispherx Enters into Sale/Leaseback Agreement for NJ Development and Production Facility

GlobeNewswire January 17, 2018

Hemispherx Enhances Manufacturing Efficiency of Ampligen

GlobeNewswire January 11, 2018

Hemispherx Announces Presentation of New-Found Properties of Ampligen at Immuno-Oncology Frontiers Conference, Jan 24

GlobeNewswire January 9, 2018

Hemispherx Biopharma CEO Discusses 2017 Highlights on CEOLIVE.TV

GlobeNewswire January 2, 2018